sustain 6 trial semaglutide SUSTAIN 6 - PIONEER6 trial semaglutide Trial The SUSTAIN 6 Trial: Semaglutide's Cardiovascular Impact in Type 2 Diabetes

PIONEER6 trial semaglutide The SUSTAIN 6 trial stands as a pivotal study in understanding the cardiovascular benefits of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.2016年11月11日—Semaglutide reduces cardiovascular risk in diabetics: The SUSTAIN-6 trial ... 1. The two-year risk of developing cardiovascular death, nonfatal ... This rigorously designed, randomized, double-blind, placebo-controlled, noninferiority trial was specifically conducted to evaluate cardiovascular and other long-term outcomes with semaglutide in adults with type 2 diabetes and a high risk of cardiovascular events. The findings from SUSTAIN 6 have significantly contributed to the evidence base surrounding semaglutide's role beyond glycemic controlSemaglutide and Cardiovascular Outcomes in Patients ....

Study Design and Patient Population

The SUSTAIN 6 trial enrolled a substantial cohort of 3,297 patients diagnosed with type 2 diabetesSeries: Cardiovascular outcome trials for diabetes drugs .... These participants were further characterized by having established cardiovascular disease or at least one additional cardiovascular risk factor. Patients were maintained on their standard-care regimen for diabetes management and were then randomly assigned to receive either once-weekly semaglutide (at doses of 02016年11月11日—Semaglutide reduces cardiovascular risk in diabetics: The SUSTAIN-6 trial ... 1. The two-year risk of developing cardiovascular death, nonfatal ....5 mg or 1 mg) or a placebo.2016年12月9日—SUSTAIN-6 was part of the global phase 3a trial programme for semaglutide, which includedsix separate clinical trials of over 7000 patients. The trial was event-driven, meaning its duration was determined by the occurrence of a pre-specified number of major adverse cardiovascular events (MACE).作者：M Husain·2020·被引用次数：57—Both clinicaltrialprograms included car- diovascular outcomestrials(CVOTs):SUSTAIN 6(s.c.semaglutide) and PIONEER 6 (oralsemaglutide) [13, 26]. In these ... The initial publication of the SUSTAIN 6 results in 2016 demonstrated a significant reduction in these events for those treated with semaglutide.

Key Cardiovascular Outcomes

The primary objective of the SUSTAIN 6 trial was to establish the noninferiority of subcutaneous semaglutide compared to placebo in terms of cardiovascular safety.SUSTAIN‐6: cardiovascular safety of a once‐weekly GLP‐ ... However, the trial also revealed a notable benefit.作者：SP Marso·2016·被引用次数：7369—The preapprovalTrialto Evaluate Cardiovascular and Other Long-term Outcomes withSemaglutidein Subjects with Type 2 Diabetes (SUSTAIN-6) was ... For the composite endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke, semaglutide demonstrated a statistically significant reductionAbstract 4137914: Eligibility for Semaglutide in US Adults .... Specifically, semaglutide reduced the combined risk of nonfatal MI, nonfatal stroke, or cardiovascular death by 26% compared to placebo. This finding was achieved within the context of the SUSTAIN 6 study, showcasing a significant cardiovascular benefit.

Furthermore, subsequent analyses of the SUSTAIN 6 data have explored various aspects of cardiovascular risk. For instance, one study looked at cardiovascular outcomes by baseline and changes in HbA1c, while another post-hoc analysis of the SUSTAIN 6 trial examined the effect of semaglutide on cardiovascular events, finding a clinically relevant benefit that persisted throughout the two-year duration of the trial. The SUSTAIN 6 trial confirmed non-inferiority for MACE, with nominal superiority, and demonstrated a significant reduction in the risk of non-fatal strokeSUSTAIN-6 - subcutaneous semaglutide and .... The significance of these findings is underscored by the fact that semaglutide reduces cardiovascular risk in diabetics, a crucial consideration for a condition often accompanied by increased cardiovascular burden.

Exploring Specific Endpoints and Considerations

Beyond the primary cardiovascular endpoints, the SUSTAIN 6 trial also provided insights into other outcomes and potential risks.SUSTAIN-6 - subcutaneous semaglutide and ... It was observed that subcutaneous semaglutide was associated with a higher risk of diabetic retinopathy complications than placebo. The authors noted that most of these events occurred early in the trial.Semaglutide reduces cardiovascular risk in diabetics This specific finding is important for clinicians and patients to be aware of when initiating semaglutide therapy.SUSTAIN-6confirmed non-inferiority for MACE, with nominal superiority, and demonstrated a significant reduction in the risk of non-fatal stroke. There was no ...

The SUSTAIN 6 study is part of a larger program for semaglutide, which includes six separate clinical trials of over 7000 patients.作者：M FISHER·2021·被引用次数：2—SUSTAIN-6compared semaglutide and placeboin 3,297 people with type 2 diabetes and estab- lished cardiovascular disease, chronic kidney disease, or both, or ... This comprehensive development program aims to thoroughly assess the efficacy and safety of semaglutide across different patient populations and treatment durations2016年9月16日—SUSTAIN 6included 3,297 patients with type 2 diabetes on a standard diabetes care regimen randomized to once-weeklysemaglutideor placebo for .... The SUSTAIN 6 results have been influential, with pooled data from SUSTAIN 6 and the PIONEER 6 trial of oral semaglutide further reinforcing the cardiovascular benefits. In these combined trials, the hazard ratio for the effect of semaglutide versus placebo on overall MACE was 0.76.

Continued Research and Future Implications

The legacy of the SUSTAIN 6 trial continues to inform clinical practice and ongoing research. The SUSTAIN 6 trial is a key reference point for understanding semaglutide's effects. Efforts are ongoing to estimate the number of US adults with T2DM who may be eligible for semaglutide based on SUSTAIN 6 eligibility criteria. The insights gained from SUSTAIN 6 and its sister trials have been instrumental in positioning semaglutide as a valuable therapeutic option for individuals with type 2 diabetes, particularly those at high cardiovascular risk. The trial also highlighted the importance of considering semaglutide in SUSTAIN 6 for its impact beyond glycemic control, focusing on a broader spectrum of patient well-being.